Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02873221 · ClinicalTrials.gov registry record · Phase 3
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,254
- Enrollment target
NCT02873221: Completed Phase 3 study, sponsored by Allergan.
NCT02873221 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 1,254 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02873221, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,254 participants
- Enrollment target
Study Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Primary Outcome
An adverse event (AE) is any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. TEAEs are
Interventions
- DRUG Ubrogepant
- DRUG Usual Care
- DRUG Placebo-matching Ubrogepant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,254 participants |
| Start Date | 2016-09-13 |
| Est. Completion | 2018-08-02 |
| Phase | Phase 3 |
What the finished NCT02873221 record still lists
NCT02873221 is an interventional study that assigns participants to a tested intervention. Its 1,254 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (62% higher).
The record links to 0 conditions, and to 3 interventions - of which Ubrogepant is the first listed.
NCT02873221 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02873221 about?
NCT02873221 is a clinical study titled "An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine". This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
What is the current status of trial NCT02873221?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,254 participants. The study started on 2016-09-13. Estimated completion is 2018-08-02.
What interventions are being tested in trial NCT02873221?
The interventions under investigation include: Ubrogepant (DRUG), Usual Care (DRUG), Placebo-matching Ubrogepant (DRUG).
Who is sponsoring clinical trial NCT02873221?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02873221's enrollment target sits among peer trials
1,254 206th of 2000 higher than 1,795 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02743858 · 1,250 participants
Lymphedema Surveillance Study
- NCT04670874 · 1,250 participants
Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29
- NCT04807868 · 1,250 participants
AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL)
- NCT05995821 · 1,250 participants
Immunobiology Blood and Tissue Collection of Upper Aerodigestive Malignancies
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI